Search Results - "Alfaro, B Marzal"

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co‐administration by Lorenzo‐Pinto, A., Giménez‐Manzorro, Á., Rodríguez‐González, C. G., Ahumada‐Jiménez, A., Herranz‐Alonso, A., Marzal‐Alfaro, M. B., Sanjurjo‐Sáez, M.

“…Summary What is known and objective Limited data are available on co‐administration of acenocoumarol with direct‐acting antiviral agents for chronic hepatitis…”
Get full text

3PC-023 A risk analysis method to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety by Marzal Alfaro, B, Rodríguez-González, CG, Escudero-Vilaplana, V, Revuelta-Herrero, JL, Ibáñez-Garcia, S, García Martín, E, González-Haba, E, Iglesias-Peinado, I, Herranz, A, Sanjurjo-Saez, M

“…BackgroundThe implementation of technology for chemotherapy compounding is recommended by several organisations to improve patient safety. However, a careful…”
Get full text

5PSQ-136 A pharmaceutical care programme in patients undergoing cardiac surgery by Ibañez Garcia, S, Garcia Gonzalez, X, Ribed Sanchez, A, de Lorenzo-Pinto, A, Giménez Manzorro, A, Ortega-Navarro, C, Marzal Alfaro, B, Garcia Martin, E, Herranz Alonso, A, Sanjurjo Sáez, M

“…BackgroundThe preoperative setting is an area with high risk for medication errors with potentially severe consequences. Strategies to reduce the incidence of…”
Get full text

4CPS-113 Drug cost saving resulting from metastatic melanoma clinical trials by García Moreno, FJ, González-Haba Peña, E, Sánchez Fresneda, MN, García Martín, E, García Sánchez, S, Marzal Alfaro, B, Collado Borrell, R, Mur Mur, A, Herranz Alonso, A, Sanjurjo Sáez, M

“…BackgroundThe development of checkpoint inhibitors-based immunotherapy has completely changed the therapeutic approach of metastatic melanoma (MM). In…”
Get full text

4CPS-112 Assessment of aggressive care in oncology patients at the end of life in clinical practice by García Martín, E, Escudero Vilaplana, V, Collado Borrell, R, González-Haba Peña, E, Marzal Alfaro, B, Fox, B, Hoyo Muñoz, Á, Martínez Ortega, PA, Amor García, MÁ, Herranz Alonso, A, Sanjurjo Saéz, M

“…BackgroundThe correct management of oncology patients at the end of life, with less aggressive interventions and open access to hospice care, affects their…”
Get full text

5PSQ-067 Analysis of antineoplastic drugs preparation errors as a first step to improve the quality of the process by Alfaro, B Marzal, Escudero-Vilaplana, V, Rodríguez-González, CG, Peña, E González-Haba, García-González, X, Ibañez-García, S, García-Moreno, FJ, Ortega-Navarro, C, Iglesias-Peinado, I, Herranz, A, Sanjurjo-Saez, M

“…BackgroundAntineoplastic preparation presents unique safety concerns because of its toxicity and narrow therapeutic window. Moreover, the antineoplastic use…”
Get full text

Efficacy of urea for treatment of patients with euvolemic hyponatremia by Lopez-Berastegui, O, Marzal-Alfaro, B, Duran-Garcia, E, Julian-Romero, M.San, Cabrera-Aguilar, J, Muiño-Miguez, A

Get full text

DI-054 Safety results of direct acting antivirals for the treatment of hepatitis C virus infection by Lallana-Sáinz, E, Giménez-Manzorro, A, Ruiz-Martínez, C, Vega, E Chamorro de, Ribed, A, Alfaro, B Marzal, Sarobe-González, C, Tovar-Pozo, M, Herranz-Alonso, A, Sanjurjo-Sáez, M

“…BackgroundThe recent development of new drugs has changed radically the treatment of chronic hepatitis C virus (HCV) infection, from interferon (IFN) based…”
Get full text

DI-053 Adherence, quality of life and patient satisfaction with dalfampridine in clinical practice by Alfaro, B Marzal, Martin-Barbero, ML, Ribed, A, Revuelta, JL, Tovar-Pozo, M, De Lorenzo-Pinto, A, Navarro, C Ortega, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundMobility impairment is a major concern for patients with multiple sclerosis (MS). Dalfampridine improves walking speed. Nevertheless, it entails…”
Get full text

Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project by Chamorro-de-Vega, Esther, Rodriguez-Gonzalez, Carmen Guadalupe, Gimenez-Manzorro, Alvaro, de Lorenzo-Pinto, Ana, Iglesias-Peinado, Irene, Herranz, Ana, Sanjurjo, Maria

“…Pharmaceutical care is needed in hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAA). We describe the implementation of a…”
Get more information

Failure mode and effects analysis to improve quality in clinical trials by Mañes-Sevilla, M, Marzal-Alfaro, M B, Romero Jiménez, R, Herranz-Alonso, A, Sanchez Fresneda, M N, Benedi Gonzalez, J, Sanjurjo-Sáez, M

“…The failure mode and effects analysis (FMEA) has been used as a tool in risk management and quality improvement. The objective of this study is to identify the…”
Get more information

PP-037 Risk of microbial contamination of pharmacy sterile preparations: A risk based decision matrix by Navarro, C Ortega, López, MS Pernia, Revuelta, JL, Pozo, M Tovar, Martínez, C Ruiz, García, B Monje, Alfaro, MB Marzal, Jiménez, RM Romero, Alonso, A Herranz, Sáez, M Sanjurjo

“…BackgroundIn order to adapt Spanish regulations to the principles set out in the European Resolution CM/ResAP(2011)1 on quality and safety assurance…”
Get full text

4CPS-127 Development of a stratification model for ambulatory oncology pharmacy patients by Revuelta Herrero, JL, Marzal-Alfaro, MB, Escudero-Vilaplana, V, Collado-Borrell, R, de Lorenzo-Pinto, A, González Haba-Peña, E, García-Sánchez, R, Sánchez-Fresneda, MN, Herranz-Alonso, A, Sanjurjo-Saéz, M

“…BackgroundTo our knowledge, there is no pharmacy stratification model for patients in the oncology ambulatory setting.PurposeTo develop a tool to stratify…”
Get full text

2SPD-008 Subgroup analysis of patients treated with trastuzumab emtansine by Ortega, P Martinez, Gonzalez-Haba, E, Marzal-Alfaro, B, Garcia-Martin, E, Garcia-Moreno, F, Ortega-Navarro, C, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundTrastuzumab emtansine (T-DM1) was studied in the EMILIA trial as a second line of treatment for HER-2 positive metastatic breast cancer (MBC),…”
Get full text

CP-212 Effectiveness and safety of new direct acting antivirals for the treatment of hepatitis C infection: Preliminary data in a coinfected HIV/HCV population by Rodriguez-Gonzalez, CG, Vega, E Chamorro-De, Gimenez-Manzorro, A, Ruiz-Martinez, C, Marzal-Alfaro, B, Collado-Borrell, R, Sarobe-Gonzalez, C, Revuelta-Herrero, JL, Herranz-Alonso, A, Sanjurjo-Saez, M

“…BackgroundIn 2015, the development of well tolerated and highly effective direct acting antivirals (DAAs) for hepatitis C virus (HCV) dramatically changed the…”
Get full text

CP-066 Decreased inr after acenocoumarol and ombitasvir/paritaprevir/ritonavir co-administration by De Lorenzo-Pinto, A, Rodríguez-González, CG, Giménez-Manzorro, A, Manrique-Rodríguez, S, Ibáñez-García, S, Escudero-Vilaplana, V, Marzal-Alfaro, B, Herranz-Alonso, A, Revuelta-Herrero, JL, Sanjurjo-Sáez, M

“…BackgroundLimited data are available regarding co-administration of acenocoumarol with direct acting antiviral agents.PurposeWe report a case of a patient who…”
Get full text

PP227-SUN EFFECT OF PARENTERAL GLUTAMINE SUPPLEMENT ON TOTAL LYMPHOCYTE COUNT IN BLOOD IN SURGICAL PATIENTS by Gomez, I. Yeste, Jimenez, R.M. Romero, Vilaplana, V. Escudero, Alfaro, B. Marzal, De Lorenzo Pinto, A, Lopez, I. Garcia, Fernandez, L. Cortejoso, De Santiago, I. Ansoleaga, Sanjurjo Saez, M

Get full text

Systemic cytomegalovirus infection: changes in serum calcium and magnesium levels with foscarnet treatment by Marzal-Alfaro, M B, Manrique-Rodríguez, S, Alcaraz Romero, A, García San Prudencio, M, Fernández-Llamazares, C M

“…Cytomegalovirus infection is common in cardiac transplant patients. Foscarnet is used, with limited evidence, as second-line treatment after ganciclovir…”
Get full text

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration by de Lorenzo-Pinto, A., Giménez-Manzorro, Á., Rodríguez-González, C. G., Ahumada-Jiménez, A., Herranz-Alonso, A., Marzal-Alfaro, M. B., Sanjurjo-Sáez, M.

Get full text

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration by de Lorenzo-Pinto, A, Giménez-Manzorro, Á, Rodríguez-González, C G, Ahumada-Jiménez, A, Herranz-Alonso, A, Marzal-Alfaro, M B, Sanjurjo-Sáez, M

“…WHAT IS KNOWN AND OBJECTIVELimited data are available on co-administration of acenocoumarol with direct-acting antiviral agents for chronic hepatitis C virus…”
Get full text